Thiazolidinediones block tumor necrosis factor-α-induced inhibition of insulin signaling

Journal of Clinical Investigation

Volumn 100, Issue 7, 1997, Pages 1863-1869

  Peraldi, Pascal ^a   Xu, Min ^a   Spiegelman, Bruce M ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Adipocytes; Antidiabetic drugs; Insulin resistance; Insulin signaling; NIDDM

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; CELL NUCLEUS RECEPTOR; INSULIN; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE 1; PHOSPHATIDYLINOSITOL 3 KINASE; PIOGLITAZONE; RETINOID X RECEPTOR; TRANSCRIPTION FACTOR; TROGLITAZONE;

ADIPOCYTE; ANIMAL CELL; ARTICLE; DRUG ACTIVITY; ENZYME ACTIVATION; HORMONE ACTION; INSULIN RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 0030885575     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI119715     Document Type: Article

References (48)

1. Iwamoti, Y., T. Kuzuya, A. Matsuda, T. Awata, S. Kumakura, G. Inooka, and I. Shiraishi. 1991. Affects of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patient with NIDDM. Diabetes Care. 14: 1083-1086.
2. Suter, S.L., J.J. Nolan, P. Wallace, B. Gumbiner, and J.M. Olefsky. 1992. Metabolic effects of new oral hypoglicemic agent CS-045 in NIDDM subjects. Diabetes Care. 15:193-203.
3. Nolan, J.J., B. Ludvik, P. Beersden, M. Joyce, and J. Olefsky. 1994. Improvement of glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N. Eng. J. Med. 331:1188-1193.
4. Tominaga, M., M. Igarashi, M. Daimon, H. Eguchi, M. Matsumoto, A. Sekiwaka, K. Yamamoti, and H. Sasaki. 1993. Thiazolidinediones (AD-4533 and CS-045) improve hepatic insulin resistance in streptozotocin-induced diabetic rats Endocr. J. 40:343-349.
5. Stevenson, R.W., R.K. McPherson, B.E. Genereux, B. Danbury, and D.K. Kreutter. 1991. Antidiabetic agent englitazone enhances insulin action in nondiabetic rats without producing hypoglycemia. Metabolism. 40:1268-1274.
6. Saltiel, A.R., and J.M. Olefsky. 1996. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes. 45:1661-1669.
7. Lehman, J.M., L.B. Moore, T.A. Smith-Oliver, W.O. Wilkison, T.M. Wilson, and S.A. Kliewer. 1995. An antidiabetic thiazolidinedione is a high affinity ligand for peroxysome proliferalor-activated receptor γ. J. Biol. Chem. 270: 12953-12956.
8. Forman, B.M., P. Tontonoz, J. Chen, R.P. Brun, B.M. Spiegelman, and R.M. Evans. 1995. 15-deoxy-d12,14-prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ. Cell. 83:803-812.
9. Tontonoz, P., E. Hu, and B.M. Spiegelman. 1994. Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor. Cell. 79: 1147-1156.
10. Spiegelman, B.M., and J.S. Flier. 1996. Adipogenesis and obesity: rounding out the big picture. Cell. 87:377-389.
11. Hotamisligil, G.S., P. Peraldi, and B.M. Spiegelman. 1996. The molecular link between obesity and diabetes. Curr. Opin. Endocrinol. Diabetes. 3:16-23.
12. Hotamisligil, G.S., N.S. Shargill, and B.M. Spiegelman. 1993. Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science (Wash. DC). 259:87-91.
13. Hofmann, C., K. Lorenz, S.S. Braithwaite, J.R. Colca, B.J. Palazuk, G.S. Hotamisligil, and B.M. Spiegelman. 1994. Altered gene expression for tumor necrosis faetor-α and its receptors during drug and dietary modulation of insulin resistance. Endocrinology. 134:264-270.
14. Hamann, A., H. Benecke, Y. Le Marchand-Brustel, V.S. Susulic, B.B. Lowell, and J.S. Flier. 1995. Characterization of insulin resistance and NIDDM in transgenic mice with reduced brown fat. Diabetes. 44:1266-1273.
15. Hotamisligil, G.S., P. Arner, J.F. Caro, R.L. Atkinson, and B.M. Spiegelman. 1995. Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance. J. Clin. Invest. 95:2409-2415.
16. Kern, P., M. Saghizadeh, J. Ong, R. Bosch, R. Deem, and R. Simsolo. 1995. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J. Clin. Invest. 95:2111-2119.
17. Ofei, F., S. Hurel, J. Newkirk, M. Sopwith, and R. Taylor. 1996. Effects of an engineered human anti-TNF-α antibody (CPD571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes. 45:881-885.
18. Hotamisligil, G.S., A. Budavari, D. Murray, and B.M. Spiegelman. 1994. Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. J. Clin. Invest. 94:1543-1549.
19. Hotamisligil, G.S., D.L. Murray, L.N. Choy, and B.M. Spiegelman. 1994. Tumor necrosis factor α inhibits signaling from the insulin receptor. Proc. Natl. Acad. Sci. USA. 91:4854-4858.
20. Feinstein, R., H. Kanety, M.Z. Papa, B. Lunenfeld, and A. Karasik. 1993. Tumor necrosis factor-α supresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates J. Biol. Chem. 268:26055-26058.
21. Kroder, G., B. Bossenmayer, M. Kellerer, E. Capp, B. Stoyanov, A. Muhlhofer, L. Berti, H. Horikoshi, A. Ullrich, and H. Haring. 1996. Tumor necrosis factor α and hyperglycemia-induced insulin resistance. J. Clin. Invest. 97:1471-1477.
22. Peraldi, P., G.S. Hotamisligil, W.A. Buurman, M.F. White, and B.M. Spiegelman. 1996. Tumor necrosis factor (TNF)-α inhibits insulin signaling through stimulation of the p55 TNF receptor and activation of sphingomyelinase. J. Biol. Chem. 271:13018-13022.
23. Hotamisligil, G.S., P. Peraldi, A. Budavari, R. Ellis, M.F. White, and B.M. Spiegelman. 1996. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-α-and obesity-induced insulin resistance. Science (Wash. DC). 271:665-668.
24. Stephens, J., and P. Pekala. 1991. Transcriptional repression of the C/EBP-alpha and GLUT4 genes in 3T3-L1 adipocytes by tumor necrosis factor-alpha. Regulations is coordinate and independent of protein synthesis. J. Biol. Chem. 267:13580-13584.
25. Garcia de Herreros, A., and M. Birnbaum. 1989. The acquisition of increased insulin-responsive hexose transport in 3T3-L1 adipocytes correlates with expression of a novel transporter gene. J. Biol. Chem 264:19994-19999.
26. Van Obberghen, E., M. Kasuga, A. Le Cam, J.A. Hedo, A. Itin, and L.C. Harrison. 1981. Biosynthetic labeling of insulin receptor: studies of subunits in cultured human IM9 lymphocytes. Proc. Natl. Acad. Sci. USA. 78:1052-1056.
27. Okada, T., Y. Kawano, T. Sakakibara, O. Hazeki, and M. Ui. 1994. Essential role of phosphatidylinositol-3-kinase in insulin-induced glucose transport and antilipolysis in rat adipocytes. Studies with a selective inhibitor wortmannin. J. Biol. Chem. 269:3568-3573.
28. Martin, S., T. Haruta, A. Morris, A. Klippel, L. Williams, and J. Olefsky. 1996. Activated phosphatidylinositol 3-kinase is sufficient to mediate actin rearrangement and GLUT4 translocation in 3T3-L1 adipocytes. J. Biol. Chem. 271: 17605-17608.
29. Tanti, J., T. Gremeaux, S. Grillo, V. Calleja, A. Klippel, L. Williams, E. Van Obberghen, and Y. Le Marchand-Brustel. 1996. Overexpression of a constitutively active form of phosphatidylinositol 3-kinase is sufficient to promote Glut 4 translocalion in adipocytes. J. Biol. Chem. 271:25227-25232.
30. Kliewer, S.A., J.M. Lenhard, T.M. Willson, I. Patel, D.C. Morris, and J.M. Lehman. 1995. A prostaglandin J2 metabolite binds PPAR-γ and promotes adipocyte differentiation. Cell. 83:813-819.
31. Boehni, M., L. Zhang, L. Zhi, M. McClurg, E. Berger, M. Wagoner, D. Mais, C. Suto, J. Davies, R. Heyman, et al. 1995. Design and synthesis of potent retinoid X receptor selective ligands that induce apoptosis in leukemia cells. J. Med. Chem. 38:3146-3155.
32. Kobayashi, M., M. Iwananishi, K. Egawa, and Y. Shigeta. 1992. Pioglitazone increases insulin sensitivity by activating insulin receptor kinase. Diabetes. 41:476-483.
33. Iwanashi, M., and M. Kobayashi. 1993. Effect of pioglitazone on insulin receptors of skeletal muscles from high fat fed rats. Metabolism. 42:1017-1021.
34. Young, P.W., M.A. Cawthorne, P.J. Coyle, J.C. Holder, G.D. Holman, I.J. Kozka, D.M. Kirkham, C.A. Lister, and S.A. Smith. 1995. Repeat treatment of obese mice with BRL 49653, a new and potent insulin sensitizer, enhances insulin action in white adipocytes. Diabetes. 44:1087-1092.
35. Zhang, B., D. Szalkowski, E. Diaz, N. Hayes, R. Smith, and J. Berger. 1994. Potentiation of insulin stimulation of phosphatidylinositol 3-kinase by thiazolidinedione-derived antidiabetic agents in CHO cells expressing human insulin receptors and L6 myotubes. J. Biol. Chem. 269:25735-25741.
36. Kreutter, D.K., K.M. Andrews, E.M. Gibbs, N.J. Hutson, and R.W. Stevenson. 1990. Insulin-like activity of new antidiabetic agent CPD68722 in 3T3-L1 adipocytes. Diabetes. 39:1414-1419.
37. Sandouk, T., D. Reda, and C. Hofman. 1993. The antidiabetic agent pioglitazone increases expression of glucose transporter in 3T3-F442A cells by increasing messenger ribonucleic acid transcript stability. Endocrinology. 133: 352-359.
38. El-Kebbi, I.M., S. Roser, and R.J. Pollet. 1994. Regulation of glucose transport by pioglitazone in cultured muscle cells. Metabolism. 43:953-958.
39. Maegawa, H., R. Ide, M. Hasegawa, S. Ugi, K. Egawa, M. Iwanishi, R. Kikkawa, Y. Shigeta, and A. Kashiwagi. 1995. Thiazolidine derivatives ameliorate high glucose-induced insulin resistance via the normalization of protein-tyrosine phosphatase activities. J. Biol. Chem. 270:7724-7730.
40. Szalkowski, D., S. White-Carrington, J. Berger, and B. Zhang. 1995. Antidiabetic thiazolidinediones block the inhibitory effect of TNF-α on differentiation, insulin stimulated glucose uptake, and gene expression in 3T3-L1 cells. Endocrinology. 136:1474-1481.
41. Ohsumi, J., S. Sakakibara, J. Yamaguchi, K. Miyadai, S. Yoshioka, T. Fujiwara, H. Horikoshi, and N. Serizawa. 1994. Troglitazone prevents the inhibitory effects of inflammatory cytokines on insulin-induced adipocytes differentiation in 3T3-L1 cells. Endocrinology. 135:2279-2282.
42. Miles, P., O. Romeo, K. Higo, K. Rafaat, and J. Olefsky. 1997. The mechanism of TNF-α-induced insulin resistance in vivo and its prevention by troglitazone. Diabetes. In press.
43. Mukherjee, R., P.J.A. Davies, D.L. Crombie, E.D. Bischoff, R.M. Cesario, L. Jow, L.G. Hamann, M.F. Boehm, C.E. Mondon, A.M. Nadzan, et al. 1997. Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature (Lond.). 386:407-410.
44. Saghizadeh, M., J.M. Ong, T.W. Garvey, R. Henry, and P.A. Kern. 1996. The expression of TNF-α by human muscle. J. Clin. Invest. 97:1111-1116.
45. Randle, P.J., E.A. Newsholme, and P.B. Garland. 1964. Regulation of glucose uptake by muscle. Effects of fatty acids, ketone bodies, and pyruvate, and of alloxan-diabetes and starvation on the uptake of metabolic fate of glucose in rat heart and diaphragm muscles. Biochem. J. 93:652-665.
46. De Vos, P., A.-M. Lefebvre, S.G. Miller, M. Guerre-Millo, K. Wong, R. Saladin, L.G. Haman, B. Staels, M.R. Briggs, and J. Auwerx. 1996. Thiazolidinediones repress ob gene expression in rodents via activation of PPAR-γ. J. Clin. Invest. 98:1004-1009.
47. Zhang, E., M.P. Graziano, T.W. Doebber, M.D. Leibowitz, S. White-Carrington, D.M. Szalkowski, P.J. Hey, M. Wu, C.A. Cullinam, P. Bailey, et al. 1996. Down-regulation of the expression of the obese gene by an antidiabetic thiazolidinedione in Zucker diabetic fatty rats and db/dh mice. J. Biol. Chem. 271:9455-9459.
48. Nolan, J., J. Olefsky, M. Nyce, R. Considine, and J. Caro. 1996. Effect of troglitazone on leptin production. Studies in vitro and in human subjects. Diabetes. 45:1276-1278.